Short-term androgen suppression produces inferior survival compared with long-term androgen suppression in the treatment of locally advanced prostate cancer, according to the results of a study published in the New England Journal of Medicine.
Among prostate patients treated with androgen deprivation therapy, the investigational drug denosumab increases bone density and reduces the risk of fractures. Denosumab also improves bone density in breast cancer patients treated with aromatase inhibitors. These were the results of two studies presented at the 2009 annual meeting the American Society of Clinical Oncology (ASCO).
Among men treated with radical prostatectomy and found to have pT3 prostate cancer (cancer that extends beyond the prostate capsule), adjuvant treatment with radiation therapy reduces the risk of post-treatment PSA increase. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.